These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 16438959)

  • 1. The nucleotide derivatives inosine and inosinic acid inhibit intestinal absorption of mizoribine in rats.
    Okada M; Suzuki K; Nakashima M; Nakanishi T; Fujioka N
    Eur J Pharmacol; 2006 Feb; 531(1-3):140-4. PubMed ID: 16438959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study on intestinal absorption sites of mizoribine and ribavirin, substrates for concentrative nucleoside transporter(s), in rats.
    Mori N; Yokooji T; Kamio Y; Murakami T
    Eur J Pharmacol; 2010 Feb; 628(1-3):214-9. PubMed ID: 19961845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of intestinal absorption of mizoribine mediated by concentrative nucleoside transporters in rats.
    Mori N; Yokooji T; Kamio Y; Murakami T
    Eur J Pharmacol; 2008 May; 586(1-3):52-8. PubMed ID: 18371949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation in concentrative nucleoside transporters-mediated intestinal absorption of mizoribine, an immunosuppressive agent, in lipopolysaccharide-treated rats.
    Mori N; Shimomukai Y; Yokooji T; Ishiguro M; Kamio Y; Murakami T
    Pharmazie; 2011 Mar; 66(3):207-11. PubMed ID: 21553652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased intestinal absorption of mizoribine, an immunosuppressive agent, in cholestatic rats.
    Mori N; Yokooji T; Kamio Y; Murakami T
    Pharmazie; 2010 Jul; 65(7):457-60. PubMed ID: 20662310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Membrane transport mechanisms of mizoribine in the rat intestine and human epithelial LS180 cells.
    Ishida K; Takaai M; Yotsutani A; Taguchi M; Hashimoto Y
    Biol Pharm Bull; 2009 Apr; 32(4):741-5. PubMed ID: 19336917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mizoribine: mode of action and effects in clinical use.
    Yokota S
    Pediatr Int; 2002 Apr; 44(2):196-8. PubMed ID: 11896886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypouricemic effects of novel concentrative nucleoside transporter 2 inhibitors through suppressing intestinal absorption of purine nucleosides.
    Hiratochi M; Tatani K; Shimizu K; Kuramochi Y; Kikuchi N; Kamada N; Itoh F; Isaji M
    Eur J Pharmacol; 2012 Sep; 690(1-3):183-91. PubMed ID: 22709993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of salt intake on bioavailability of mizoribine in healthy Japanese males.
    Ishida K; Fukao M; Watanabe H; Taguchi M; Miyawaki T; Matsukura H; Uemura O; Zhang Z; Unadkat JD; Hashimoto Y
    Drug Metab Pharmacokinet; 2013; 28(1):75-80. PubMed ID: 22813716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of ribonucleotide reductase activity and nucleic acid synthesis in tumor cells by the dialdehyde derivatives of inosine (NSC 118994) and inosinic acid.
    Cory JG; Mansell MM; Whitford TW
    Cancer Res; 1976 Sep; 36(9 pt.1):3166-70. PubMed ID: 987850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the effects of mizoribine with those of azathioprine, 6-mercaptopurine, and mycophenolic acid on T lymphocyte proliferation and purine ribonucleotide metabolism.
    Dayton JS; Turka LA; Thompson CB; Mitchell BS
    Mol Pharmacol; 1992 Apr; 41(4):671-6. PubMed ID: 1569921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Guanine ribonucleotide depletion inhibits T cell activation. Mechanism of action of the immunosuppressive drug mizoribine.
    Turka LA; Dayton J; Sinclair G; Thompson CB; Mitchell BS
    J Clin Invest; 1991 Mar; 87(3):940-8. PubMed ID: 1999502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of concentrative nucleoside transporter 1 gene polymorphism on oral bioavailability of mizoribine in stable kidney transplant recipients.
    Naito T; Tokashiki S; Mino Y; Otsuka A; Ozono S; Kagawa Y; Kawakami J
    Basic Clin Pharmacol Toxicol; 2010 Apr; 106(4):310-6. PubMed ID: 19912163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic study of mizoribine in an adolescent with lupus nephritis.
    Abe Y; Tsuji Y; Hisano M; Nakada M; Miura K; Watanabe S; Odajima Y; Iikura Y
    Pediatr Int; 2004 Oct; 46(5):597-600. PubMed ID: 15491391
    [No Abstract]   [Full Text] [Related]  

  • 15. Contribution of Na+-independent nucleoside transport to ribavirin uptake in the rat intestine and human epithelial LS180 cells.
    Takaai M; Morishita H; Ishida K; Taguchi M; Hashimoto Y
    Eur J Pharmacol; 2008 Dec; 601(1-3):61-5. PubMed ID: 19013148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical significance of blood level monitoring of mizoribine in kidney transplantation.
    Ihara H; Shinkuma D; Nojima M; Koike H; Yabumoto H; Yamanaka Y; Ikoma F
    Transplant Proc; 1994 Aug; 26(4):2029-31. PubMed ID: 8066660
    [No Abstract]   [Full Text] [Related]  

  • 17. Population pharmacokinetics of mizoribine in pediatric recipients of renal transplantation.
    Ishida K; Motoyama O; Shishido S; Tsuzuki K; Hashimoto Y
    Clin Exp Nephrol; 2012 Oct; 16(5):799-804. PubMed ID: 22367565
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mizoribine, an inhibitor of inosine monophosphate dehydrogenase, inhibits interleukin-6 production by freshly prepared rheumatoid synovial cells.
    Sugiyama E; Ikemoto M; Taki H; Maruyama M; Yamashita N; Kobayashi M
    Mod Rheumatol; 2001 Mar; 11(1):28-33. PubMed ID: 24387017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population Pharmacokinetic Analysis of Mizoribine in Chinese Renal Transplant Recipients.
    Liu L; Ren B; Zhang H; Li J; Fu Q; Jiang J; Deng S; Qiu J; Chen G; Fei J; Chen L; Wang C
    Transplant Proc; 2018 Oct; 50(8):2392-2397. PubMed ID: 30316364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetics of mizoribine in pediatric patients with kidney disease.
    Kaneda H; Shimizu M; Ohta K; Ushijima K; Gotoh Y; Satomura K; Nagai T; Fujieda M; Morooka M; Yamada T; Yamada M; Wada N; Takaai M; Hashimoto Y; Uemura O
    Clin Exp Nephrol; 2016 Oct; 20(5):757-763. PubMed ID: 26649561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.